Exhibit Hall Theater
.png)
Progress continues toward the development of disease models, stem cell manufacturing and tissue engineered products in microgravity that will change the paradigm of regenerative medicine. This session will provide insights into the ongoing initiatives by Axiom Space, the leading provider of human spaceflight services and developer of human-rated infrastructure, to build dedicated research and manufacturing facilities, establish state-of-the-art capabilities and biomanufacturing applications for Axiom Station that will shape the future of cGMP manufacturing in low-Earth Orbit. This session will discuss how Private/Commercial Astronaut Missions to the International Space Station that Axiom operates today are providing increased opportunities for access to microgravity that are accelerating the pace of development for biomedical applications and share a view of what the future of in-space biomanufacturing will look like on the world’s first commercial space station - Axiom Station, the successor to the International Space Station.